S1198
Clinical - Urology
ESTRO 2026
reported. Results:
radiotherapy for high risk and node positive prostate cancer. Keywords: high risk prostate cancer, prostate SBRT
The study included 31 patients of whom only six were treated before 2024. The median age was 74 years (IQR:63-82); ECOG 0-1 was reported in 26 patients and ECOG 2 in five patients. Tumor stages were: T1a- 25 patients, T1b- 3 patients, the rest- T3-T4. Median pre- SABR eGFR was 57.0 ml/min/1.73m2 (IQR:45-75). Most patients (n=23) were disqualified from surgery due to comorbidities, and eight declined surgery. Twelve patients had contralateral kidney cancer, and 11 patients had a solitary kidney. The pathology confirmation was available in seven patients. Six patients had a recurrence after prior nephron-sparing surgery or ablation. SABR schedules included 5 x 6-10 Gy (15 patients), 1 x 24-26 Gy (11 patients) and 3 x 9-14 Gy (5 patients). After a median follow-up of 10 months, 1-year LC was 94%. Acute G1 adverse events (fatigue, nausea, pain) occurred in eight patients and G2 event (fatigue) was noted in one patient. Only one patient developed late G1 adverse event (pain). The median 1- year decrease in eGFR was 5.5 ml/min/1.73m2 (IQR:1- 10). Conclusion: SABR for primary kidney cancer remains underutilized in Poland and is predominantly applied in elderly or comorbid patients. However, its use has markedly increased since the ISRS consensus publication in 2024. Early results confirm favorable tolerability and LC, supporting the growing confidence in SABR as a non-invasive treatment for selected patients. Keywords: kidney cancer, SBRT, primary tumor Reirradiation of local recurrences of prostate cancer: PROSTARE (PROstate cancer STereotActic REirradiation) early safety analysis of a phase 2 study Wojciech Majewski 1,2 , Aleksandra Napieralska 1,3 , Marcin Miszczyk 4,5 , Anna Misiorowska-Golosz 1 , Marcela Krzempek 6 , Malgorzata Stapor-Fudzinska 7 , Justyna Rembak-Szynkiewicz 8 , Jerzy Wydmanski 1,2 1 Radiotherapy Department, Maria Sklodowska Curie National Research Institute of Oncology, Gliwice, Poland. 2 Department of Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. 3 Radiothrapy Clinic, Maria Sklodowska Curie National Research Institute of Oncology, Krakow, Poland. 4 Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 5 Collegium Medicum, Faculty of Medicine, WSB University, Dabrowa Gornicza, Poland. 6 Department of Biostatistics and Bioinformatics,, Maria Sklodowska Curie National Research Institute of Oncology, Gliwice, Poland. Poster Discussion 1850
Digital Poster 1847
Evolving use of stereotactic ablative radiotherapy for primary renal cancer in Poland: results of a multicenter retrospective analysis Wojciech Majewski 1,2 , Barlomiej Tomasiik 3,4 , Mateusz Bilski 5,6 , Konrad Stawiski 7 , Grzegorz Majewski 1,8 , Agata Ciepiela 1 , Krzysztof Konopa 3 1 Radiotherapy Department, Maria Sklodowska Curie National Research Institute of Oncology, Gliwice, Poland. 2 Department of Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland. 3 Department of Oncology and Radiotherapy, Medical University of Gda ń sk, Gda ń sk, Poland. 4 Centre for Experimental Cardiooncology, Medical University of Gda ń sk, Gda ń sk, Poland. 5 Department of Radiotherapy, Affidea Nu-md Center of Oncological Diagnostis and Therapy, Zamosc, Poland. 6 Clinics of Radiotherapy, Medical University of Lublin, Lublin, Poland. 7 Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland. 8 Student Research Group at the Department of Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland Purpose/Objective: Stereotactic ablative body radiotherapy (SABR) has emerged as a promising option for patients with primary renal cancer who are medically inoperable or refuse surgery. Despite growing evidence of its safety and efficacy, the use of SABR for renal cancer in routine clinical practice remains limited. Following the publication of the International Stereotactic Radiosurgery Society (ISRS) consensus guidelines in 2024, we conducted a retrospective multicenter analysis to evaluate the implementation, clinical characteristics, and early outcomes of SABR for primary kidney cancer across Polish radiotherapy centers. Material/Methods: Four centers with documented experience with SABR contributed data for patients with primary kidney cancer treated between 2016 and mid-2025. Histopathological confirmation was not mandatory when MRI findings were unequivocally consistent with malignancy. The analysis focused on the patient characteristics and utilization of SABR in this indication throughout the study period with a special emphasis on the period after the publication of ISRS guidelines. The early results on local control (LC) and adverse events (CTCAE), and eGFR decrease were also
Made with FlippingBook - Share PDF online